243 related articles for article (PubMed ID: 31922238)
1. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
Bu H; Li Y; Jin C; Yu H; Wang X; Chen J; Wang Y; Ma Y; Zhang Y; Kong B
Int J Oncol; 2020 Mar; 56(3):685-696. PubMed ID: 31922238
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
5. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
[TBL] [Abstract][Full Text] [Related]
6. High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.
You S; Han X; Xu Y; Sui L; Song K; Yao Q
Cancer Med; 2024 May; 13(10):e7217. PubMed ID: 38752472
[TBL] [Abstract][Full Text] [Related]
7. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
8. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
Li R; Wu H; Jiang H; Wang Q; Dou Z; Ma H; Yan S; Yuan C; Yang N; Kong B
Oncol Rep; 2020 Nov; 44(5):2143-2151. PubMed ID: 32901854
[TBL] [Abstract][Full Text] [Related]
9. LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer.
Zeng Z; Ji N; Yi J; Lv J; Yuan J; Lin Z; Liu L; Feng X
Cancer Biomark; 2020; 28(1):65-72. PubMed ID: 32176632
[TBL] [Abstract][Full Text] [Related]
10. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
11. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
12. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract][Full Text] [Related]
13. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
[TBL] [Abstract][Full Text] [Related]
14. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
16. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
[TBL] [Abstract][Full Text] [Related]
17. Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells.
Li Y; Guo H; Wang Z; Bu H; Wang S; Wang H; Fang H; Liu Z; Kong B
Exp Cell Res; 2020 Oct; 395(2):112212. PubMed ID: 32771525
[TBL] [Abstract][Full Text] [Related]
18. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
19. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
[TBL] [Abstract][Full Text] [Related]
20. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
